Microparticles comprising tirzepatide or pharmaceutically acceptable salt thereof, and manufacturing method therefor

HK40137469APending Publication Date: 2026-09-11INVENTAGE LAB INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026126285
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-01-10
Filing Date
2026-07-17
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present application relates to a kind of microparticles comprising tirzepatide or its pharmaceutically acceptable salt and a method for preparing the same, by increasing the content of tirzepatide or its pharmaceutically acceptable salt in the microparticles, the drug loading amount in the microparticles is increased, and the microparticles continuously exhibit the release effect of tirzepatide or its pharmaceutically acceptable salt without initial burst release and lag-time, so as to prevent excessive decrease in bioavailability. In addition, when used as a subcutaneous injection, the amount of microparticles contained in a single injection can be reduced, thereby reducing the pain at the administration site, and no inflammatory reaction occurs.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202580007347.5 (22) Application Date 2025.01.10 (30) Priority Data 10-2024-0004289 2024.01.10 KR (85) PCT International Application Entering National Phase Date 2026.06.10 (86) PCT International Application Application Data PCT / KR2025 / 000604 2025.01.10 (87) PCT International Application Publication Data WO2025 / 150965 KO 2025.07.17 (71) Applicant: Chuangji Co., Ltd. Address: Gyeonggi Province, South Korea (72) Inventors: Kim Joo-hee, Lee Sang-ro (74) Patent Agency: Beijing Zhifan Vision Intellectual Property Agency Co., Ltd. 11890 Patent Attorney Su Zhilian (51) Int.Cl. A61K 9 / 16 (2006.01) A61K 9 / 00 (2006.01) A61K 38 / 22 (2006.01) (54) Invention Title: Microparticles Containing Thiropeptide or a Pharmaceutically Acceptable Salt Thereof and Method for Preparing Them (57) Abstract: This invention relates to microparticles containing thiopeptide or a pharmaceutically acceptable salt thereof and method for preparing the same. By increasing the content of thiopeptide or a pharmaceutically acceptable salt in the microparticles, the drug loading in the microparticles is increased, and the microparticles continuously exhibit the release effect of thiopeptide or a pharmaceutically acceptable salt thereof without initial burst release and lag time, thereby preventing excessive decrease in bioavailability. In addition, when used as a subcutaneous injection, the amount of microparticles contained in a single injection can be reduced, thereby reducing pain at the administration site and preventing inflammatory reactions. Claims (2 pages), Description (13 pages), Drawings (14 pages), CN 122374012 A 2026.07.10 CN 1 22 37 40 12 A 1. A microparticle containing telpolide or a pharmaceutically acceptable salt thereof, characterized in that it contains telpolide or a pharmaceutically acceptable salt thereof and a biodegradable polymer, said biodegradable polymer containing poly(lactic-co-glycolic acid) (PLGA). 2. The microparticle containing telpolide or a pharmaceutically acceptable salt thereof according to claim 1, wherein the pore size of the surface and interior of the microparticle is adjusted to inhibit the initial burst release of telpolide or a pharmaceutically acceptable salt thereof when the microparticle is injected into the body. 3. The microparticle containing telpolide or a pharmaceutically acceptable salt thereof according to claim 2, wherein, in a SEM image at a magnification of ×2.0k, the pores inside the cross-section of the microparticle are uniformly distributed in size, forming a dense tissue structure.4. The microparticles comprising telposide or a pharmaceutically acceptable salt thereof according to claim 2, wherein the surface of the microparticles is porosilicate-removed, forming a smooth surface in a SEM image at a magnification of ×2.0k. 5. The microparticles comprising telposide or a pharmaceutically acceptable salt thereof according to claim 1, wherein the intrinsic viscosity of the polylactide-glycolic acid (PLGA) is less than 0.2 dl / g, and the molar ratio of lactide to glycolide is 50:50. 6. The microparticles comprising telposide or a pharmaceutically acceptable salt thereof according to claim 1, wherein the content of telposide or a pharmaceutically acceptable salt thereof is 10% by weight or more relative to the total weight of the microparticles. 7. The microparticles comprising telposide or a pharmaceutically acceptable salt thereof according to claim 1, wherein the average diameter of the microparticles is 30 to 70 μm. 8. A sustained-release injectable composition comprising telposide or a pharmaceutically acceptable salt thereof, characterized in that it comprises the microparticles according to any one of claims 1 to 7. 9. The sustained-release injectable composition comprising telposide or a pharmaceutically acceptable salt thereof according to claim 8, wherein the injectable composition continuously releases telposide or a pharmaceutically acceptable salt thereof in vivo for more than one month via a single injection. 10. A method for preparing microparticles comprising telposide or a pharmaceutically acceptable salt thereof, characterized by comprising the following steps: dissolving telposide or a pharmaceutically acceptable salt thereof and a biodegradable polymer in an organic solvent to prepare an oil phase solution; mixing a surfactant and water to prepare an aqueous phase solution; using the oil phase solution and the aqueous phase solution to form an emulsion comprising telposide or a pharmaceutically acceptable salt thereof; and collecting and solidifying the formed emulsion comprising telposide or a pharmaceutically acceptable salt thereof to prepare microparticles comprising telposide or a pharmaceutically acceptable salt thereof; wherein the aqueous phase solution further comprises a property modifier. 11. The method for preparing microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to claim 10, wherein the concentration of the aqueous phase solution is 0.1 to 10 (w / v)% by mixing with a property improver. 12. The method for preparing microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to claim 10, wherein, in the step of forming an emulsion containing telpolide or a pharmaceutically acceptable salt thereof using an oil phase solution and an aqueous phase solution, the oil phase solution and the aqueous phase solution are injected into each channel by microfluidic methods, and an emulsion is formed at the intersection of the flow phases of the oil phase solution and the aqueous phase solution. 13. The method for preparing microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to claim 10, wherein the organic solvent is selected from the group consisting of methanol, chloroform, chloromethane, dichloromethane, trichloroethane, ethanol, dimethyl sulfoxide, and mixtures thereof.14. The method for preparing microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to claim 10, wherein the oil phase solution contains telpolide or a pharmaceutically acceptable salt thereof and a biodegradable polymer in a weight ratio of 1:3 to 1:15. Claims 2 / 2 Page 3 CN 122374012 A Microparticles containing telpolide or a pharmaceutically acceptable salt thereof and method for preparing the same Technical Field

[0001] The present invention relates to microparticles containing telpolide or a pharmaceutically acceptable salt thereof and method for preparing the same. Background Art

[0002] In recent years, with economic development and changes in dietary habits, the incidence of metabolic syndrome-related diseases, including obesity, hyperlipidemia, hypertension, arteriosclerosis, hyperinsulinemia, diabetes, or liver disease, is increasing dramatically. Although these diseases sometimes occur alone, they are usually closely related to each other, and in most cases, multiple symptoms occur simultaneously.

[0003] Overweight and obesity can raise blood pressure and cholesterol levels, becoming a cause of onset or exacerbation of various diseases such as heart disease, diabetes, and arthritis. In addition, overweight and obesity are major factors contributing to the increased incidence of arteriosclerosis, hypertension, hyperlipidemia, or heart disease not only in adults but also in children and adolescents.

[0004] Obesity is a complex disease related to the mechanisms of appetite regulation and energy metabolism. Because methods are needed to treat both the abnormal mechanisms of appetite regulation and energy metabolism simultaneously, there is ongoing research into drugs that can treat these abnormal mechanisms. As a result of these efforts, obesity treatments such as rimonaban (Sanofi-Aventis), sibutramin (Abbott), Contrave (Takeda), and orlistat (Roche) have been developed, but they have drawbacks such as exhibiting fatal side effects or minimal efficacy in treating obesity. For example, rimonaban has been reported to cause central nervous system disorders, sibutramin and Contrave have been reported to cause cardiovascular side effects, and orlistat has only shown a weight loss of about 4 kg after one year of use.

[0005] On the other hand, metabolic syndrome, including obesity, also increases the likelihood of developing liver disease. Examples include metabolic liver disease, fatty liver, non-alcoholic fatty liver disease, steatohepatitis, and liver fibrosis. These liver diseases are on the rise due to increasing obesity and diabetes, with an annual incidence rate of approximately 16% in South Korea. Early-stage liver diseases often present no noticeable symptoms and are frequently only discovered after the disease has progressed to a considerable stage. Therefore, they are among the leading causes of death not only in South Korea but also globally, necessitating urgent drug development.

[0006] For such treatments of obesity, glucagon-like peptide-1 (GLP-1) is a hormone secreted by the small intestine in response to food intake. It promotes insulin secretion from the pancreas and inhibits glucagon secretion in a glucose concentration-dependent manner, thus helping to lower blood glucose levels. Additionally, it acts as a satiety factor, slowing down gastrointestinal digestion and delaying the gastric transit time of digested food, thereby reducing food intake.

[0007] GLP-1, one of the gastrointestinal hormones secreted in response to food intake, is a 42-amino acid hormone secreted by the K cells of the small intestine. It promotes insulin secretion from the pancreas in a glucose concentration-dependent manner and helps lower blood glucose levels. It has been reported to have effects such as increasing GLP-1 activity, anti-inflammatory effects, and improving lipid metabolism.

[0008] Therefore, therapeutic agents for diabetes and obesity are being actively developed using the blood glucose-regulating and weight-reducing effects of GLP-1. However, the rate of HbA1c reduction by GLP-1 alone is less than 0.5% to 1.8%, and is therefore considered suitable for patients with HbA1c below 9% (Ther Adv Endocrinol Metab. 2015 Feb; 6(1): 3-18). That is, there are predictable limitations in the glycemic regulation capacity of GLP-1 alone.

[0009] To this end, research has been conducted on dual-acting agents that can simultaneously activate GLP-1 and GIP receptors. A representative commercial product of this type is Tirzepatide, marketed under the brand name Mounjaro, which is an antidiabetic drug for the treatment of type 2 diabetes. Tirzepatide is administered once a week via subcutaneous injection.

[0010] As mentioned above, Tirzepatide has the inconvenience of requiring weekly subcutaneous injection. To eliminate this problem, it is necessary to develop an injectable formulation that can exert the pharmacological effects of Tirzepatide for more than one month with a single injection.

[0011] Prior Art Documents Patent Document KR 10-2021-0110349 A1 Summary of the Invention Technical Problem to be Solved The object of the present invention is to provide a microparticle containing telpolide or a pharmaceutically acceptable salt thereof and a method for preparing the same.

[0012] Another object of the present invention is to provide a microparticle containing telpolide or a pharmaceutically acceptable salt thereof and a method for preparing the same, which, by increasing the content of telpolide or a pharmaceutically acceptable salt thereof in the microparticles, increases the drug loading in the microparticles, and the microparticles continuously exhibit the release effect of telpolide or a pharmaceutically acceptable salt thereof without initial burst release and lag time, thereby preventing excessive decline in bioavailability.

[0013] Another object of the present invention is to provide a microparticle containing telpolide or a pharmaceutically acceptable salt thereof and a method thereof for preparation thereof, which, as an injectable for subcutaneous injection, can reduce the amount of microparticles contained in the injectable during a single injection, thereby reducing pain at the administration site and preventing inflammatory reactions.

[0014] Technical Solution to the Technical Problem In order to achieve the above object, the present invention relates to a microparticle containing telpolide or a pharmaceutically acceptable salt thereof, comprising telpolide or a pharmaceutically acceptable salt thereof and a biodegradable polymer, wherein the biodegradable polymer comprises poly(lactic-co-glycolic acid) (PLGA).

[0015] In addition, the surface and internal pore size of the microparticles are adjusted so that when the microparticles are injected into the body, the initial burst release of telpolide or a pharmaceutically acceptable salt thereof can be suppressed.

[0016] Furthermore, in a SEM image with a magnification of ×2.0k, the pores inside the cross-section of the microparticles can be uniformly distributed in size, forming a dense tissue structure.

[0017] Furthermore, the surface of the microparticles is porosized, resulting in a smooth surface in a SEM image at a magnification of ×2.0k.

[0018] Furthermore, the intrinsic viscosity of the polylactide-glycolic acid (PLGA) can be less than 0.2 dl / g, and the molar ratio of lactide to glycolide can be 50:50.

[0019] Furthermore, the content of telpolide or a pharmaceutically acceptable salt thereof relative to the total weight of the microparticles can be 10% by weight or more.

[0020] Furthermore, the average diameter of the microparticles can be 30 to 70 μm.

[0021] Another aspect of the present invention for achieving the above objectives relates to a sustained-release injectable composition comprising telpolide or a pharmaceutically acceptable salt thereof, which comprises the microparticles.

[0022] Furthermore, the injectable composition can sustainably release telpolide or a pharmaceutically acceptable salt thereof in vivo for more than one month via a single injection.

[0023] Another aspect of the present invention for achieving the above objective relates to a method for preparing microparticles containing telpoide or a pharmaceutically acceptable salt thereof, comprising the following steps: dissolving telpoide or a pharmaceutically acceptable salt thereof and a biodegradable polymer in an organic solvent to prepare an oil phase solution; mixing a surfactant and water to prepare an aqueous phase solution; using the oil phase solution and the aqueous phase solution to form an emulsion containing telpoide or a pharmaceutically acceptable salt thereof; and collecting and solidifying the formed emulsion containing telpoide or a pharmaceutically acceptable salt thereof to prepare microparticles containing telpoide or a pharmaceutically acceptable salt thereof; wherein the aqueous phase solution further comprises a property improver.

[0024] In addition, by mixing the property improver, the concentration of the aqueous phase solution may be from 0.1 to 10 (w / v)%.

[0025] Furthermore, in the step of forming an emulsion containing telpolide or a pharmaceutically acceptable salt thereof using an oil phase solution and an aqueous phase solution, the oil phase solution and the aqueous phase solution are injected into each channel by microfluidic methods, and an emulsion can be formed at the intersection of the flow phases of the oil phase solution and the aqueous phase solution.

[0026] Furthermore, the organic solvent may be selected from the group consisting of methanol, chloroform, chloromethane, dichloromethane, trichloroethane, ethanol, dimethyl sulfoxide, and mixtures thereof.

[0027] Furthermore, the oil phase solution may contain telpolide or a pharmaceutically acceptable salt thereof and a biodegradable polymer in a weight ratio of 1:3 to 1:15.

[0028] Effects of the Invention The present invention increases the drug loading in the microparticles by increasing the content of telpolide or a pharmaceutically acceptable salt thereof in the microparticles, and the microparticles continuously exhibit the release effect of telpolide or a pharmaceutically acceptable salt thereof without initial burst release and lag time, thereby preventing excessive decline in bioavailability.

[0029] Furthermore, when used as a subcutaneous injection, the amount of microparticles contained in a single injection can be reduced, thereby alleviating pain at the administration site and preventing inflammatory reactions. Brief Description of the Drawings

[0030] Figure 1 shows the pharmacokinetic results of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0031] Figure 2 shows the pharmacokinetic results of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0032] Figure 3 shows the pharmacokinetic results of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0033] Figure 4 shows the pharmacokinetic results of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0034] Figure 5 shows the pharmacokinetic results of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0035] Figure 6 shows the pharmacokinetic results of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0036] Figure 7 shows the pharmacokinetic results of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0037] Figure 8 is a SEM image of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0038] Figure 9 is a SEM image of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0039] Figure 10 is a SEM image of microparticles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention. (See page 3 / 13 of the specification, CN 122374012 A)

[0040] FIG11 is a SEM image of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0041] FIG12 is a SEM image of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0042] FIG13 is a SEM image of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0043] FIG14 is a SEM image of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0044] FIG15 is a SEM image of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0045] FIG16 is a SEM image of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0046] FIG17 is a SEM image of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0047] Figure 18 is a SEM image of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0048] Figure 19 is a SEM image of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0049] Figure 20 shows the pharmacokinetic results of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0050] Figure 21 shows the pharmacokinetic results of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0051] Figure 22 shows the pharmacokinetic results of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0052] Figure 23 shows the pharmacokinetic results of particles containing telpolide or a pharmaceutically acceptable salt thereof according to an embodiment of the present invention.

[0053] Preferred Embodiment The present invention relates to a microparticle comprising telpolide or a pharmaceutically acceptable salt thereof, comprising telpolide or a pharmaceutically acceptable salt thereof and a biodegradable polymer comprising poly(lactic-co-glycolic acid) (PLGA). Detailed Description

[0054] Hereinafter, embodiments of the present invention will be described in detail to enable those skilled in the art to readily implement the present invention. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein.

[0055] Obesity is one of the most common nutritional disorders worldwide. According to WHO statistics, approximately 250 million people are currently classified as obese, and it is predicted that approximately 300 million people will suffer from obesity in 20 years.

[0056] Obesity refers to a state of excessive accumulation of body fat due to an imbalance in calorie metabolism caused by excessive energy intake or reduced energy expenditure. In recent years, due to the Western-style diet and lack of exercise among modern people, the incidence of obesity has shown a sharp increasing trend.

[0057] In addition, from a numerical perspective, a body mass index (BMI) of 25 or higher is defined as obesity. The BMI measurement method is an obesity measurement method that estimates body fat by dividing weight (kg) by the square of height (m²).

[0058] Trizepatide is marketed under the trade name Mounjaro. Clinical trials have shown that Trizepatide resulted in an average weight reduction of 18% when taken at the maximum dose. Thiopletide is a dual-action therapeutic agent of glucose-dependent insulinotropic peptide (GIP) / glucagon-like peptide-1 (GLP-1). GLP-1 reduces appetite and increases satiety by stimulating insulin secretion, while GIP breaks down fat cells and alleviates nausea.

[0059] In addition, it has been shown to be effective in treating heart failure in recent years, with a confirmed reduction of 38% in the risk of cardiovascular death and other serious illnesses. Therefore, it is not only effective in weight loss, but also in improving symptoms such as heart disease that lead to serious health risks.

[0060] However, the side effects of thiopletide are similar to those of smegglutide. Gastrointestinal symptoms such as nausea and diarrhea may occur. The administration method is also the same as that of smegglutide, with the patient administering the drug subcutaneously once a week.

[0061] In order to eliminate the above problems, efforts are being made to release thiopletide or its pharmaceutically acceptable salts for more than one month through a single subcutaneous injection to maintain the efficacy. To this end, long-acting formulations are being developed using biodegradable polymers as sustained-release agents.

[0062] A sustained-release formulation of the biodegradable polymeric telpolide or its pharmaceutically acceptable salt may be a microparticle containing the telpolide or its pharmaceutically acceptable salt.

[0063] The microparticle contains a biodegradable polymer and a telpolide or its pharmaceutically acceptable salt. When the microparticle is injected into the body, it slowly decomposes in the body, releasing the telpolide or its pharmaceutically acceptable salt.

[0064] Typically, the microparticle decomposes in the body for more than one month, releasing the telpolide or its pharmaceutically acceptable salt, thereby exhibiting effects such as weight loss or improvement of symptoms of heart disease.

[0065] However, such microparticles are difficult to produce with a uniform particle size during preparation, and therefore may not be able to sustain release for up to one month.

[0066] In addition, excessive release of the telpolide or its pharmaceutically acceptable salt may typically occur in the initial stage of injection.

[0067] Furthermore, due to the low encapsulation efficiency of telpolide or its pharmaceutically acceptable salt in the microparticles, or the small weight ratio to the biodegradable polymer, a large number of microparticles need to be injected in a single injection, thus causing pain or inflammation at the injection site.

[0068] To prevent such problems, the present invention may relate to a microparticle containing telpolide or its pharmaceutically acceptable salt, comprising telpolide or its pharmaceutically acceptable salt and a biodegradable polymer, said biodegradable polymer comprising polylactide-glycolic acid (PLGA).

[0069] As described above, the microparticles of the present invention are intended to be provided as a sustained-release formulation containing telpolide or its pharmaceutically acceptable salt.

[0070] In addition, the microparticles comprise a biodegradable polymer, said biodegradable polymer may comprise polylactide-glycolic acid (PLGA).

[0071] More specifically, the intrinsic viscosity of the polylactide-glycolic acid (PLGA) may be less than 0.2 dl / g, and the molar ratio of lactide to glycolide may be 50:50.

[0072] The microparticles containing the polylactide-glycolic acid (PLGA) as described above slowly increase drug release from page 5 / 13 of the initial specification (CN 122374012 A) without lag time, thereby continuously exhibiting the release effect of telpolide or its pharmaceutically acceptable salt for more than one month.

[0073] For this purpose, the microparticles of the present invention, as biodegradable polymers, may contain polylactide-glycolic acid (PLGA) with an intrinsic viscosity of less than 0.2 dl / g and a molar ratio of lactide to glycolide of 50:50.

[0074] In addition, the microparticles of the present invention may contain one or more biodegradable polymers.

[0075] When one of the biodegradable polymers is included, it may refer to polylactide-glycolic acid (PLGA) containing only one of the following: an intrinsic viscosity of less than 0.2 dl / g and a molar ratio of lactide to glycolide of 50:50; when two or more are included, it may refer to polylactide-glycolic acid (PLGA) containing only one of the following: an intrinsic viscosity of less than 0.2 dl / g and a molar ratio of lactide to glycolide of 50:50.

[0076] Therefore, when two or more biodegradable polymers are included, in addition to the polylactide-glycolic acid (PLGA) with an intrinsic viscosity of less than 0.2 dl / g and a molar ratio of lactide to glycolide of 50:50, it may further include polylactide-glycolic acid (PLGA) with a molar ratio of lactide to glycolide of 75:25, polylactide-glycolic acid (PLGA) with a molar ratio of lactide to glycolide of 65:35, etc., and in addition to the polylactide-glycolic acid (PLGA), it may further include biodegradable polymers selected from polylactic acid, polylactide, polylactic acid-glycolic acid copolymer, polyphosphazene, polyimide carbonate, polyphosphate, polyanhydride, polyorthoester, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, and mixtures thereof.

[0077] However, when microparticles are prepared using polylactide-glycolic acid (PLGA) containing an intrinsic viscosity of 0.2 dl / g or less and a molar ratio of lactide to glycolide of 50:50, as described above, although the microparticles exhibit drug release from the initial stage without lag time, initial burst release may become a problem.

[0078] Furthermore, in the microparticles of the present invention, the content of telpolide or its pharmaceutically acceptable salt relative to the total weight of the microparticles can be 10% by weight or more, 11% by weight or more, 12% by weight or more, 13% by weight or more, 14% by weight or more, 15% by weight or more, or 16% by weight or more. By keeping the content of telpolide or its pharmaceutically acceptable salt in the microparticles within the above range as described above, the drug content is increased, thereby reducing the amount of microparticles administered by a single injection. As described above, increasing the content of telpolide or its pharmaceutically acceptable salt in the microparticles can exhibit the above-described effects, but like the aforementioned biodegradable polymers, it may become a factor initiating initial burst release.

[0079] That is, as described above, existing sustained-release formulations containing telpolide or its pharmaceutically acceptable salts, when using biodegradable polymers to prevent initial burst release, suffer from the problem of insufficient effect at the initial injection stage due to the delay time; even when other biodegradable polymers are used to prevent this problem, increasing the content of telpolide or its pharmaceutically acceptable salts within the particles to reduce the amount of particles administered per dose still results in the problem of initial burst release.

[0080] When preparing sustained-release formulations using biodegradable polymers, the type of biodegradable polymer and the content of telpolide or its pharmaceutically acceptable salts in the particles become factors closely related to initial burst release.

[0081] In order to eliminate the above-mentioned problems and exhibit drug release from the initial injection stage without delay time, the present invention aims to eliminate the above-mentioned problems by adjusting the properties of the particles.

[0082] That is, when the microparticles of the present invention are used as an injectable composition, although drug release is observed from the initial stage without lag time, initial burst release is not a problem, and the release effect of telpolide or its pharmaceutically acceptable salt can be observed for more than one month.

[0083] Specifically, the surface and internal pore size of the microparticles of the present invention are adjusted so that when the microparticles are injected into the body, the initial burst release of telpolide or its pharmaceutically acceptable salt can be suppressed.

[0084] The microparticles with adjusted surface and internal pore size are characterized, more specifically, in a SEM image at a magnification of ×2.0k, the internal pores on the cut section are uniformly distributed in size, forming a dense tissue structure, and the surface has multiple uniformly sized pores, forming a smooth surface in a SEM image at a magnification of ×2.0k.

[0085] When preparing spherical microparticles using biodegradable polymers, the presence of multiple pores on the interior and surface of the biodegradable polymer can be confirmed by SEM images. The presence or absence of pores on the surface of the microparticles can be easily confirmed by SEM images, and the internal pores of the microparticles can be confirmed by SEM images of the microparticle cross-section.

[0086] In particular, when the magnification is adjusted to ×2.0k to confirm the microparticles, it can be confirmed that multiple pores are formed on the surface and interior, and the pore sizes vary. Through the surface and internal pores as described above, the microparticles injected into the body can slowly decompose as water permeates into the pores.

[0087] That is, when preparing the microparticles using biodegradable polymers, multiple pores with various diameters can be formed on the interior and surface. However, the occurrence of the aforementioned initial burst release, delay time, etc., can be determined by these multiple pores.

[0088] Therefore, in this invention, to eliminate the above-mentioned problems, a property modifier is used to adjust the internal and surface pores to a smaller size, resulting in a smooth surface shape and a dense internal structure.

[0089] The property improver is selected from the group consisting of sodium chloride (NaCl), potassium chloride (KCl), calcium chloride (CaCl2), magnesium sulfate (MgSO4), sodium sulfate (Na2SO4), mannitol, ammonium, potassium sulfate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, sodium citrate, trisodium citrate, and sodium succinate. Sodium chloride (NaCl) is preferred, but the method is not limited to the above examples. Any property improver that can be adjusted to have the properties of the present invention described above can be used without limitation.

[0090] The average diameter of the particles can be 30 to 70 μm, 30 to 60 μm, or 30 to 50 μm. Furthermore, the standard deviation of the average diameter can be 1 to 30 μm, 1 to 20 μm, 1 to 10 μm, or 1 to 7 μm.It can be confirmed that uniform particles can be prepared within the diameter range. When the uniform particles are used as a sustained-release injection, the foreign body sensation can be reduced, the convenience of administration can be improved, and the initial burst release can be prevented when injected into the body, exhibiting a sustained release effect of telpolide or its pharmaceutically acceptable salt.

[0091] The span value of the particles of the present invention can be 1.2 or less, 0.7 or less, 0.5 or less, or 0.4 or less. More specifically, the span value of the particles of the present invention can be 0.2 to 0.4. Particles with a span value within the range mean that the particle diameter is very uniform. By injecting the uniform particles as described above into the body, the initial burst release of telpolide or its pharmaceutically acceptable salt can be prevented, and the release effect can be sustained for more than 1 month.

[0092] A sustained-release injection composition containing telpolide or its pharmaceutically acceptable salt according to another embodiment of the present invention may contain the particles.

[0093] The injection composition can sustainably release telpolide or its pharmaceutically acceptable salt in the body for more than 1 month with a single injection. Furthermore, as described above, since it exhibits a sustained release of telpolide or its pharmaceutically acceptable salt from the initial injection without an initial burst and without a delay time, when used as an injectable formulation, it exhibits the effect of telpolide or its pharmaceutically acceptable salt from the initial injection and can maintain a sustained effect for more than one month.

[0094] The injectable composition can be prepared by mixing the microparticles of the present invention with a suspension solvent. The suspension solvent comprises an isotonic agent, a suspending agent, and a solvent.

[0095] More specifically, the isotonic agent may be selected from the group consisting of D-mannitol, maltitol, sorbitol, lactitol, xylitol, sodium chloride, and mixtures thereof, preferably D-mannitol, but not limited to the above examples.

[0096] The suspending agent may be selected from sodium carboxymethyl cellulose, polysorbate 80, starch, starch derivatives, polyols, chitosan, chitosan derivatives, cellulose, cellulose derivatives, collagen, gelatin, hyaluronic acid (HA), alginic acid, alginate, pectin, carrageenan, chondroitin, chondroitin sulfate, dextran, dextran sulfate, polylysine, titin, fibrin, agarose, fluran, xanthan gum. The group consisting of sodium carboxymethyl cellulose and polysorbate 80 is preferred, but not limited to the examples described above.

[0097] The solvent may be water for injection, and any solvent that can be used as water for injection may be used without limitation.

[0098] According to another embodiment of the present invention, a method for preparing microparticles containing telpolide or a pharmaceutically acceptable salt thereof includes the following steps: dissolving telpolide or a pharmaceutically acceptable salt thereof and a biodegradable polymer in an organic solvent to prepare an oil phase solution; mixing a surfactant and water to prepare an aqueous phase solution; using the oil phase solution and the aqueous phase solution to form an emulsion containing telpolide or a pharmaceutically acceptable salt thereof; and collecting and solidifying the formed emulsion containing telpolide or a pharmaceutically acceptable salt thereof to prepare microparticles containing telpolide or a pharmaceutically acceptable salt thereof; the aqueous phase solution may further contain a property improver.

[0099] The oil phase solution may be prepared by dissolving telpolide or a pharmaceutically acceptable salt thereof and a biodegradable polymer in an organic solvent.

[0100] The biodegradable polymer is as described above.

[0101] The organic solvent is selected from the group consisting of methanol, chloroform, chloromethane, dichloromethane, trichloroethane, ethanol, dimethyl sulfoxide, and mixtures thereof. Preferably, a mixed solvent consisting of methanol and dimethyl sulfoxide as co-solvents and dichloromethane as solvent can be used as the organic solvent to dissolve telpolide or its pharmaceutically acceptable salt and the biodegradable polymer to prepare an oil phase solution.

[0102] The oil phase solution may contain telpolide or its pharmaceutically acceptable salts and biodegradable polymers in weight ratios of 1:3 to 1:15, 1:4 to 1:14, 1:5 to 1:13, 1:5 to 1:12, 1:5 to 1:11, 1:5 to 1:10, 1:5 to 1:9, 1:5 to 1:8, and 1:5 to 1:7. Containing telpolide or its pharmaceutically acceptable salts and biodegradable polymers within these ranges allows for sustained release of telpolide or its pharmaceutically acceptable salts for more than one month without initial burst release. Furthermore, by containing telpolide or its pharmaceutically acceptable salts and biodegradable polymers within these ranges, pain during injection can be reduced, and inflammation at the injection site can be inhibited.

[0103] The surfactant contained in the aqueous solution is selected from one or more of methylcellulose, polyvinylpyrrolidone, lecithin, gelatin, polyvinyl alcohol, sorbitan monooleate (e.g., Span™ 80, etc.), polyoxyethylene sorbitan fatty acid ester (e.g., Tween™ 80, etc.), polyoxyethylene castor oil derivatives, sodium lauryl sulfate, sodium stearate, ester amines, linear diamines, fatty amines, and mixtures thereof, preferably polyvinyl alcohol, but not limited to the above examples. Any surfactant that can be used to prepare a complete spherical emulsion can be used.

[0104] In addition to the surfactant, the aqueous solution may further contain a property improver. The content of the property improver relative to the total weight of the aqueous solution may be 0.1 wt% to 10 wt%, 0.2 wt% to 9 wt%, 0.3 wt% to 8 wt%, 0.4 wt% to 7 wt%, 0.5 wt% to 6 wt%, and 0.5 wt% to 5 wt%. When the content of the property improver is below the range, the property improvement effect is minimal, and initial burst release may become a problem; when the content exceeds 5% by weight, the initial burst release improvement effect brought about by the property improvement is indistinguishable.

[0105] The final concentration of the aqueous solution containing the property improver can be 0.1 to 10 (w / v)%, 0.1 to 9 (w / v)%, 0.1 to 8 (w / v)%, 0.1 to 7 (w / v)%, 0.1 to 6 (w / v)%, 0.1 to 5 (w / v)%, 0.5 to 5 (w / v)%. When the concentration of the aqueous solution is below the above range, the property improvement effect is minimal; when it exceeds the range, the initial burst release improvement effect brought about by the property improvement is indistinguishable.

[0106] As mentioned above, the method of preparing an emulsion using the oil phase solution and the aqueous phase solution after preparation is not limited.

[0107] In this invention, a method for preparing microparticles using microfluidics will be described.

[0108] The microchip used in the microfluidic method can be formed on a wafer or a glass substrate. Microchannels are formed on the microchip, more specifically including channels for the flow of an oil phase solution, channels for the flow of an aqueous phase solution, and transport channels. The oil phase solution channels and the aqueous phase solution channels are formed to converge at a single point, and one end of the transport channel can be connected to the junction of the two channels.

[0109] Injection portions for injecting oil phase solutions and aqueous phase solutions are respectively attached to the oil phase solution channels and the aqueous phase solution channels. One end of the transport channel can be attached to a recovery portion for recovering the solution containing the emulsion.

[0110] The microchannels can be formed on a material selected from the group consisting of a glass substrate, a silicon wafer, or a polymer film, but the examples of materials are not limited to the above examples; any material capable of forming microchannels can be used.

[0111] The polymer film may be selected from the group consisting of polyimide, polyethylene, fluorinated ethylene propylene, polypropylene, polyethylene terephthalate, polyethylene naphthalate, polysulfone, and mixtures thereof, but is not limited to the examples above.

[0112] As an example, aluminum is deposited on a silicon wafer using an electron beam evaporator, and photoresist is patterned on the aluminum using photolithography. Then, aluminum etching is performed using the photoresist as a mask. After removing the photoresist, silicon is etched using DRIE (deep ion reactive etching) using the aluminum as a mask. After removing the aluminum, positive electrode bonding glass is sealed on the wafer to prepare the microchannel described above.

[0113] The microchannels used to prepare the microparticles of the present invention can utilize a 144-channel chip. In the case of the microchip, the average diameter of the microchannels for injecting the oil phase solution and the aqueous phase solution is 300 μm to 500 μm. After moving through each channel, the oil phase solution and the aqueous phase solution can pass through a resistance channel. The average diameter of the resistance channel is 10 μm to 50 μm. After passing through the resistance channel, the oil phase solution and the aqueous phase solution pass through an intersecting junction channel, the diameter of which can be 100 μm to 400 μm.After the oil phase solution and aqueous phase solution cross and form an emulsion in the bonding channel, the emulsion passes through a microchannel with a diameter of 150 μm to 200 μm, and then through a microchannel with a diameter of 200 μm to 300 μm.

[0114] However, the average diameter of the microchannel can vary depending on the range of injection pressure and flow conditions. In addition, although the average diameter of the microchannel is closely related to the average diameter of the particles, it is also closely related to the injection pressure and flow conditions of the oil phase solution and the aqueous phase solution.

[0115] The oil phase solution and aqueous phase solution prepared as described above can flow into the first microchannel and the second microchannel forming the intersection point under the flow conditions described later.

[0116] That is, the oil phase solution flows along the first microchannel, and the aqueous phase solution flows along the second microchannel formed to intersect with the first microchannel, thereby merging with the flow of the oil phase solution.

[0117] More specifically, when the oil phase solution is injected into the first microchannel, the flow rate is 100 μL / min to 300 μL / min, or 150 μL / min to 270 μL / min.

[0118] In addition, when the aqueous phase solution is injected into the second microchannel, the flow rate is 10,000 μL / min to 30,000 μL / min, or 15,000 μL / min to 27,000 μL / min.

[0119] As described above, by making the flow rates of the oil phase solution and the aqueous phase solution different, and maintaining the flow rate of the aqueous phase solution greater than the flow rate of the oil phase solution as specified in page 9 / 13 of the specification (CN 122374012 A), at the point where the flow of the oil phase solution and the flow of the aqueous phase solution converge, the aqueous phase solution with a relatively larger flow rate compresses the oil phase solution. At this time, due to the reaction force between the oil phase solution and the aqueous phase solution, a spherical emulsion containing the biodegradable polymer in the oil phase solution and telposide or its pharmaceutically acceptable salt is formed. More specifically, an emulsion in which telposide or its pharmaceutically acceptable salt is uniformly distributed in the spherical biodegradable polymer is formed.

[0120] The temperature of the oil phase solution and the aqueous phase solution flowing in the microchannel is also 15 to 20°C, preferably 17°C. That is, after flowing in the microchannel, forming an intersection point and generating microparticles, the low temperature of 15 to 20°C is maintained constant until the collected emulsion is stirred. Only by maintaining a low temperature during the particle preparation process can spherical particles be prepared and maintained. That is, if the low temperature conditions are not met, it will be difficult to prepare particles of a certain spherical shape.

[0121] The prepared emulsion can be collected in a water tank containing an aqueous phase solution and stirred at 200 rpm to 300 rpm.

[0122] The aqueous phase solution is an aqueous phase solution prepared for the preparation of the emulsion, that is, using a mixed solution of surfactant and purified water, a portion of the prepared aqueous phase solution is injected into a microchannel and the other portion is sent to the water tank, thereby preventing the collected emulsion from coagulating.

[0123] Subsequently, the temperature is raised to 20°C to 30°C or 25°C, and the mixture is stirred for 0.5 hours to 1.5 hours or 1 hour to solidify, thereby preparing microparticles.

[0124] In order to remove residual organic solvents, the microparticles can be stirred under certain temperature conditions and stirring speed to evaporate and remove residual organic solvents in the emulsion. At this time, the stirring conditions are to stir at 200 to 400 rpm at 35°C to 45°C for 2 hours to 4 hours, specifically, to stir at 200 to 300 rpm at 35°C to 40°C for 2.5 hours to 3.5 hours, and more specifically, to stir at 200 to 300 rpm at 40°C for 3 hours.

[0125] As described above, by removing residual organic solvents under stirring conditions, very small pores are formed on the surface of the emulsion, and spherical particles with smooth surfaces can be prepared, while minimizing residual organic solvents.

[0126] Finally, the emulsion, after stirring to remove all residual organic solvents, was washed several times with sterile filtered purified water to remove residual surfactants, and then freeze-dried to prepare microparticles.

[0127] Preparation Example: Preparation of microparticles containing Tirzepatide or a pharmaceutically acceptable salt thereof. Tirzepatide (manufacturer: polypeptide) and PLGA were weighed and placed in a mixed solvent prepared by mixing the co-solvents MeOH and DMSO with DCM solvent, and dissolved uniformly to prepare an oil phase solution. The mixed solvent was prepared by mixing MeOH, DMSO and DCM in a weight ratio of 1:2:6. NaCl, as a property improver, was added to a 0.5% aqueous solution of polyvinyl alcohol to make the final concentration 0.5% (w / v)% to prepare an aqueous phase solution. The oil phase solution and the aqueous phase solution were injected into microchannels formed on a silicon wafer to allow them to flow. At this time, the flow rate ratio of the oil phase solution to the aqueous phase solution was 1:100. The temperature was maintained at 17°C. The particles generated at the intersection of the flow of the oil phase solution and the flow of the aqueous phase solution were collected in the water tank containing the aqueous phase solution. The particles collected in the water tank were stirred at 200 rpm to 300 rpm for 1 hour at 25°C to solidify the emulsion. Then, the emulsion was stirred at 200 rpm to 300 rpm for 3 hours at 40°C to remove residual organic solvents. The emulsion was washed several times with sterile filtered purified water and freeze-dried to prepare the particles.

[0128] Experimental Example 1 When preparing the particles of the preparation example according to the AP ratio to confirm the properties of the initial burst, the weight ratio of telpoeptide and biodegradable polymer was adjusted as shown in Table 1 below to prepare the oil phase solution. The aqueous phase solution did not contain property modifiers and was used to prepare particles.The microparticles were suspended in water for injection to prepare an injectable composition, and pharmacokinetic evaluation was performed. The test conditions were as follows: - Male SD rats, 6 weeks old - 10 SD rats per group (40 rats in total) were used, and the average concentration of telpolide in the blood was calculated according to the measurement time.

[0129] - Subcutaneous administration (1.24 mg / head) [Table 1]

[0130] PDLG7502A (molar ratio of lactide to glycolide of 75:25) was applied as a biodegradable polymer in Figures 1 to 3. In Figure 1, the weight ratio of Tirzepatide (manufacturer: polypeptide) to biodegradable polymer is 1:10 (drug loading: 9.1%). In Figure 2, the weight ratio is 1:7 (drug loading: 12.5%). In Figure 3, the weight ratio is 1:5 (drug loading: 16.7%). Based on Figures 1 to 3, it is confirmed that an initial burst release occurs with increasing drug concentration.

[0131] Further, as biodegradable polymers, PDLG5002A (molar ratio of lactide to glycolide of 50:50) and PDLG7502A (molar ratio of lactide to glycolide of 75:25) were mixed at a weight ratio of 1:3, and an oil phase solution was prepared with a weight ratio of Tirzepatide (manufacturer: polypeptide) to PLGA of 1:7 (Figure 4) or 1:5 (Figure 5). The aqueous phase solution did not contain a phase modifier, thereby preparing microparticles.

[0132] According to Figures 4 and 5, it was confirmed that when the weight ratio of Tirzepatide to biodegradable polymer was 1:5 due to the inclusion of PDLG5002A, a larger initial burst release occurred compared with the use of PDLG7502A alone (Figure 3).

[0133] Further, by changing the biodegradable polymer, it was confirmed whether the type of biodegradable polymer affected the initial burst release. As a biodegradable polymer, PDLG7504A (lactide to glycolide molar ratio of 75:25) or PDL02A (PLA polymer) was used to prepare an oil phase solution with a weight ratio of telpoeptide to biodegradable polymer of 1:5. The aqueous phase solution did not contain phase modifiers, thus preparing microparticles.

[0134] The experimental results are shown in Figures 6 and 7.

[0135] According to the experimental results, it was confirmed that when PDLG7504A or PDL02A was used as the biodegradable polymer, although no initial burst release occurred, after the initial release, the release of telpoeptide almost ceased.

[0136] Based on the above experiments, it was confirmed that when PLGA with a molar ratio of lactide to glycolide of 50:50 is used as a biodegradable polymer, or when the weight ratio of tirzepatide to PLGA is 1:5 and the drug loading is 16.7%, an initial burst release problem occurs.

[0137] Experimental Example 2 Evaluation of the properties of microparticles based on the presence or absence of property improvers Microparticles were prepared using the same method as described in the preparation example. As a biodegradable polymer, PDLG5002A (molar ratio of lactide to glycolide of 50:50) and PDLG7502A (molar ratio of lactide to glycolide of 75:25) were mixed at a weight ratio of 1:3. After preparation with a weight ratio of tirzepatide (manufacturer: polypeptide) to PLGA of 1:5, only the application of NaCl was changed to prepare an aqueous solution, and microparticles were prepared using it. Instruction manual, pages 11 / 13, CN 122374012 A

[0138] Figure 8 is a SEM image of the microparticles of the property improver of the preparation example of the present invention, and Figure 9 is the result of confirming the SEM image of the microparticles prepared in an aqueous solution without the property improver.

[0139] According to Figure 8, it is confirmed that the surface of the particles is formed very uniformly with almost no surface pores, and the structure is also very dense in the formation of the cut cross section.

[0140] On the other hand, according to Figure 9, it is confirmed that the surface of the particles has large pores, and the cross section structure is not dense. In addition, it is confirmed that in the process of cutting the microparticles to form a cross section, the particles cannot be cut uniformly and are prone to breakage.

[0141] Experimental Example 3 Evaluation of the properties of microparticles according to the content of property improver Microparticles were prepared by the same method as the preparation example described above. As a biodegradable polymer, PDLG5002 (lactide to glycolide molar ratio of 50:50) and PDLG7502 (lactide to glycolide molar ratio of 75:25) were mixed at a weight ratio of 1:3. After preparing an oil phase solution with a Tirzepatide (manufacturer: polypeptide) to PLGA weight ratio of 1:5, NaCl was mixed to prepare an aqueous phase solution to achieve a final concentration of 5 (w / v)%, 0.5 (w / v)%, or 0.1 (w / v)%, thereby preparing microparticles.

[0142] The results are shown in Figures 10 to 15.

[0143] In Figures 10 and 13, the final concentration of the aqueous phase solution was 5 (w / v)%. In Figures 11 and 14, the final concentration of the aqueous phase solution was 0.5 (w / v)%. In Figures 12 and 15, the final concentration of the aqueous phase solution was 0.1 (w / v)%. Figures 10 to 15 are SEM images at a magnification of 2.0k.

[0144] Figures 10 to 12 are photographs of the particle surface.Figures 10 and 11 confirm that the surface of the particles is a smooth sphere, while Figure 12 confirms that the particle surface is irregular. The irregularity and unevenness of the surface are due to the depressions in the pores or the uneven surface formation.

[0145] Figures 13 to 15 are photographs of the particle cross-section, confirming that as the content of the property improver increases, the internal pores become smaller and denser. On the other hand, it is confirmed that when the final concentration of the aqueous solution is 0.1% (w / v), due to the larger pores, the particles are not cut when cut, but rather break apart.

[0146] Further, as the types of polymers, a 1:1:1 weight ratio of RG502H (molar ratio of lactide to glycolide of 50:50) / RG504H (molar ratio of lactide to glycolide of 50:50) / RG653H (molar ratio of lactide to glycolide of 65:35) was used to prepare an oil phase solution with a weight ratio of Tirzepatide (manufacturer: polypeptide) to PLGA of 1:5. Then, NaCl was mixed in an aqueous phase solution to make the final concentrations 5 (w / v)%, 0.5 (w / v)%, 0.1 (w / v)%, and NaCl-free, respectively, thereby preparing microparticles.

[0147] The results of comparing the internal and surface properties of the microparticles based on the differences in aqueous phase solution concentrations are shown in Figures 16 to 19.

[0148] In Figure 16, the final concentration of the aqueous solution is 5 (w / v)%. In Figure 17, the final concentration of the aqueous solution is 0.5 (w / v)%. In Figure 18, the final concentration of the aqueous solution is 0.1 (w / v)%. Figure 19 shows the case using an aqueous solution without NaCl.

[0149] It was confirmed that even if the types of biodegradable polymers are kept the same, the surface and cross-sectional properties of the particles differ depending on the presence or absence of NaCl in the aqueous solution and the concentration when it is included.

[0150] Example 4 Evaluation of the inhibitory effect of the property modifier on initial burst release As a biodegradable polymer, RG502H (molar ratio of lactide to glycolide of 50:50) / RG504H (molar ratio of lactide to glycolide of 50:50) / RG653H (molar ratio of lactide to glycolide of 65:35) was contained in a weight ratio of 1:1:1. An oil phase solution was prepared by mixing RG502H (molar ratio of lactide to glycolide of 15:50) / RG653H (molar ratio of lactide to glycolide of 65:35) with a weight ratio of 1:5 for Tirzepatide (manufacturer: polypeptide) and PLGA. NaCl was then mixed to prepare an aqueous phase solution to a final concentration of 5 (w / v)% or 0.1 (w / v)%, thereby preparing microparticles. The microparticles were suspended in water for injection to prepare an injectable composition, and pharmacokinetic evaluation was performed.The experimental conditions were as follows: - Male SD rats, 7 weeks old - 10 SD rats per group (40 rats in total), and the average blood concentration of telpolide was calculated according to the measurement time - Subcutaneous administration (1.24 mg / rat) The experimental results are shown in Table 2, Figure 20 and Figure 21 below.

[0151] [Table 2]

[0152] According to the experimental results, it was confirmed that the difference in the concentration of the aqueous solution with added NaCl led to the difference in whether an initial burst release occurred. However, although the bioavailability was partially reduced when using a 5% NaCl aqueous solution compared to the case containing 0.1% NaCl, the difference was not significant.

[0153] Further, the pK release results were confirmed for the cases using 5 (w / v)% or 0.5 (w / v)% NaCl aqueous solutions, and the results are shown in Table 3, Figure 22 and Figure 23 below.

[0154] [Table 3]

[0155] The experimental results in Table 3 were obtained under the same experimental conditions as those in Table 2 above. Although the Cmax, AUC, and Tmax values ​​differed due to the differences in biodegradable polymers, the use of a 0.5% NaCl aqueous solution showed a similar inhibitory effect on the initial burst release as the use of a 5% NaCl aqueous solution.

[0156] However, as shown in Table 3, it was confirmed that the AUC decreased with increasing NaCl concentration. Therefore, the properties can be controlled by NaCl, and the initial burst release can be controlled according to the above-mentioned property control. However, the degree of decomposition of biodegradable polymers in vivo may be affected by the control of pore size, formation, etc. For this reason, when using an aqueous solution with a concentration exceeding the 5% NaCl range, the bioavailability decreased excessively, and the release effect of telpolide or its pharmaceutically acceptable salts may be minimal.

[0157] The preferred embodiments of the present invention have been described in detail above, but the scope of protection of the present invention is not limited to the above examples. Various modifications and improvements made by those skilled in the art using the basic concepts of the present invention as defined in the following claims also fall within the scope of protection of the present invention.

[0158] Industrial Applicability The present invention relates to a microparticle comprising telpolide or a pharmaceutically acceptable salt thereof and a method for preparing the same.Instruction Manual Page 13 / 13 16 CN 122374012 A Figure 1 Figure 2 Figure 3 Instruction Manual Drawings Page 1 / 14 17 CN 122374012 A Figure 4 Figure 5 Instruction Manual Drawings Page 2 / 14 18 CN 122374012 A Figure 6 Figure 7 Instruction Manual Drawings Page 3 / 14 19 CN 122374012 A Figure 8 Instruction Manual Drawings Page 4 / 14 20 CN 122374012 A Figure 9 Figure 10 Instruction Manual Drawings Page 5 / 14 21 CN 122374012 A Figure 11 Figure 12 Instruction Manual Drawings Page 6 / 14 22 CN 122374012 A Figure 13 Figure 14 Instruction Manual Drawings Page 7 / 14 23 CN 122374012 A Figure 15 Instruction Manual Drawings Page 8 / 14 24 CN 122374012 A Figure 16 Instruction Manual Drawings Page 9 / 14 Page 25 CN 122374012 A Figure 17 Appendix to the Specification 10 / 14 Page 26 CN 122374012 A Figure 18 Appendix to the Specification 11 / 14 Page 27 CN 122374012 A Figure 19 Appendix to the Specification 12 / 14 Page 28 CN 122374012 A Figure 20 Figure 21 Figure 22 Appendix to the Specification 13 / 14 Page 29 CN 122374012 A Figure 23 Appendix to the Specification 14 / 14 Page 30 CN 122374012 A.

Claims

1. A microparticle comprising telpolide or a pharmaceutically acceptable salt thereof, characterized in that, It contains telpolide or its pharmaceutically acceptable salts and biodegradable macromolecules. The biodegradable polymer comprises polylactide-glycolic acid (PLGA).

2. The microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 1, wherein, The surface and internal pore size of the microparticles are adjusted to inhibit the initial burst release of telpolide or its pharmaceutically acceptable salts when the microparticles are injected into the body.

3. The microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 2, wherein, In the SEM image at a magnification of ×2.0k, the pores inside the cut cross-section of the microparticles are uniformly distributed in size, forming a dense tissue structure.

4. The microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 2, wherein, The surface of the particles is removed by pores, resulting in a smooth surface in a SEM image with a magnification of ×2.0k.

5. The microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 1, wherein, The intrinsic viscosity of the polylactide-glycolic acid (PLGA) is below 0.2 dl / g, and the molar ratio of lactide to glycolide is 50:

50.

6. The microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 1, wherein, The content of the telpoeptide or its pharmaceutically acceptable salt is more than 10% by weight relative to the total weight of the particles.

7. The microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 1, wherein, The average diameter of the particles is 30 to 70 μm.

8. A sustained-release injectable composition comprising telpolide or a pharmaceutically acceptable salt thereof, characterized in that, It comprises the particles according to any one of claims 1 to 7.

9. The sustained-release injectable composition comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 8, wherein, The injectable composition provides sustained release of telpolide or its pharmaceutically acceptable salt in vivo for more than one month via a single injection.

10. A method for preparing microparticles comprising telpolide or a pharmaceutically acceptable salt thereof, characterized in that, Includes the following steps: An oil phase solution is prepared by dissolving telpolide or its pharmaceutically acceptable salts and biodegradable polymers in an organic solvent; Aqueous solutions are prepared by mixing surfactants and water. Using the oil phase solution and the aqueous phase solution, an emulsion containing telpolide or a pharmaceutically acceptable salt thereof is formed; as well as Collect and solidify the emulsion containing telpolide or a pharmaceutically acceptable salt thereof to prepare microparticles containing telpolide or a pharmaceutically acceptable salt thereof; The aqueous solution further contains a property improver.

11. The method for preparing microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 10, wherein, The concentration of the aqueous solution is 0.1 to 10 (w / v) by using a mixed property improver.

12. The method for preparing microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 10, wherein, In the step of forming an emulsion containing telpolide or a pharmaceutically acceptable salt thereof using an oil phase solution and an aqueous phase solution, The oil phase solution and the aqueous phase solution are injected into each channel using a microfluidic method, forming an emulsion at the intersection of the flow phases of the oil phase solution and the aqueous phase solution.

13. The method for preparing microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 10, wherein, The organic solvent is selected from the group consisting of methanol, chloroform, chloromethane, dichloromethane, trichloroethane, ethanol, dimethyl sulfoxide, and mixtures thereof.

14. The method for preparing microparticles comprising telpolide or a pharmaceutically acceptable salt thereof according to claim 10, wherein, The oil phase solution contains telpoide or a pharmaceutically acceptable salt thereof and a biodegradable polymer in a weight ratio of 1:3 to 1:15.